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Here, we present a physiologically relevant model of the human
pulmonary alveoli. This alveolar lung-on-a-chip platform is com-
posed of a three-dimensional porous hydrogel made of gelatin
methacryloyl with an inverse opal structure, bonded to a compart-
mentalized polydimethylsiloxane chip. The inverse opal hydrogel
structure features well-defined, interconnected pores with high
similarity to human alveolar sacs. By populating the sacs with pri-
mary human alveolar epithelial cells, functional epithelial mono-
layers are readily formed. Cyclic strain is integrated into the device
to allow biomimetic breathing events of the alveolar lung, which,
in addition, makes it possible to investigate pathological effects
such as those incurred by cigarette smoking and severe acute re-
spiratory syndrome coronavirus 2 pseudoviral infection. Our study
demonstrates a unique method for reconstitution of the functional
human pulmonary alveoli in vitro, which is anticipated to pave the
way for investigating relevant physiological and pathological
events in the human distal lung.
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The lung, as the major organ of the human respiratory system,is responsible primarily for gas exchanges and thus, directly
exposed to the external environment. Lungs are affected by a
plethora of pathologies such as asthma (1); chronic obstructive
pulmonary disease (COPD) (2); and infections like influenza (3),
pneumonia (4), and tuberculosis (5) as well as lung cancer (6).
These pathological manifestations make lung failure one of the
leading causes of death globally. More recently, this is further
exemplified by the coronavirus disease 2019 (COVID-19) pandemic,
which has so far killed more than 3 million people worldwide with
total confirmed cases of >140 million (7).
The lack of reliable and physiologically relevant animal models
for human respiratory diseases has led to a critical issue for new
drug development as more than 90% of the preclinical studies
performed in animals do not predict the outcome of human clinical
trials (8). This has resulted in a lack of progress in drug develop-
ment in respiratory medicine, with only a handful of new drugs
entering clinical use in the last 50 y (9). In addition, many of the
existing cell culture-based models do not replicate the key bio-
logical aspects of the human lung and do not adequately reflect the
host responses. These models range from simple two-dimensional
(2D) cultures of lung cells on polymeric or elastomeric membrane
systems to the complex biomimetic lung-on-a-chip microdevices
(10). While each of these more complex models (10–14) may have
advantages over 2D single-cell cultures, collectively they suffer
from important limitations such as use of synthetic polymer
membranes with nonphysiological stiffness to culture cells and/or
lack of mechanical stimulation (inhalation/exhalation process).
In fact, there is increasing acceptance that the composition
and topography of the extracellular matrix (ECM) have major
influences on cell functions (15) and regulate cellular responses
to various stimuli. As such, ECM features are too critical to be
ignored in the design and fabrication of any biologically relevant
tissue and disease models. Therefore, there is a clear need for
an advanced model system that not only mimics the human lung
tissue structurally but also, captures its ECM physiology that is
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essential to their functional reproduction in vitro. More impor-
tantly, there are no satisfactory models of the distal lung (i.e., the
alveolar space) that truly reflect the sac shape anatomy (16–18) to
study physiology and pathophysiology. A recent work attempted to
develop such a model with bioprinting (19); however, this model
merely reflected alveoli’s gross anatomy, albeit in much larger
scales than the actual features of the human alveoli (millimeters
vs. micrometers), and the material used was still incompatible to
native tissue in terms of bioactivity.
To address these challenges, herein we report the development
of a physiological human-based model that successfully recon-
structs the microstructure, ECM properties, air–cell interface, and
the breathing events of the pulmonary alveoli, which are the basic
units enabling gas exchanges in the human lung. This model,
termed as the “alveolar lung-on-a-chip,” is composed of a three-
dimensional (3D) porous hydrogel made of low-stiffness gelatin
methacryloyl (GelMA) featuring an inverse opal structure, bonded
to a compartmentalized polydimethylsiloxane (PDMS) chip device
that provides the medium supply, the air–liquid interface (ALI),
and the cyclic mechanical movements (Fig. 1).
Importantly, the GelMA inverse opal structure has a high
similarity to the native human alveolar sacs in that they possess
both the sac-like pores and the interconnecting windows between
the sacs, in addition to a stiffness close to the native human lung.
Due to its 3D nature, it is possible to construct ∼7,050 alveoli
within an 8 × 10 × 3-mm3 model to allow faithful physiological
emulation. Primary human alveolar epithelial cells (hAECs)
were populated on the surfaces of the sacs to form the mono-
layer epithelium. The alveolar lung model was further subjected
to cyclic inhalation/exhalation movements, as well as used to
investigate the effects of cigarette smoke and severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2) pseudoviral
infection. Our study provides a unique method for reconstitution
of functional alveolar lung-on-a-chip in vitro, potentially paving
the way for investigating a range of pathophysiology of the hu-
man distal lung, such as infectious diseases affecting the alveolar
space including COVID-19.
Results and Discussion
Fabrication of the Alveoli-Like 3D Porous Structure and Formation of
the Alveolar Epithelium. The typical process for the fabrication of
the alveoli-like 3D GelMA inverse opal structure is schematically
presented in Fig. 2 A, i, where the corresponding optical mi-
crographs are shown in Fig. 2 A, ii. This process largely follows
those published by us (20–24) and others (25–28) with modifi-
cations. First, alginate microbeads with a uniform size (201 ±
12 μm) were assembled into a cubic close-packed lattice. Then,
7% GelMA solution was infiltrated into the void spaces of the
lattice and cross-linked. Finally, after the removal of the alginate
microbeads by the 0.01 M ethylene diamine tetraacetic acid
disodium (EDTA) solution, an alveoli-like 3D hydrogel with
uniform pores and connecting windows was formed. Very limited
amount of GelMA solution was able to infiltrate the contact
areas between the microbeads prior to their removal, allowing
also formation of interconnecting windows between most, if not
all, of the adjacent pores to enable effective ventilation.
Further, 7% GelMA was chosen since it allowed sufficient
stability of the resulting sac-like structures while having a stiff-
ness close to the normal lung tissue (29). GelMA was used as the
model ECM to fabricate the scaffold due to its biocompatibility,
photocross-linkability, availability, and cost-effectiveness (30).
Importantly, GelMA possesses some of the essential properties of
ECM such as presence of arginine-glycine-aspartic acid sequences,
which promote cell attachment, and matrix metalloproteinase-
responsive peptide motifs, thus allowing cells to proliferate and
spread in/on GelMA-based scaffolds. A range of Young’s modulus
values has been reported for the human lung tissue depending on
the anatomical compartments of the lung and the mechanical
testing techniques used, from ∼1.4 to 7.2 kPa (31, 32). The com-
pressive modulus of our GelMA hydrogels (double cross-linked;
first with Irgacure 2959 and then with microbial transglutaminase
[mTG]) was found to be 6.23 ± 0.64 kPa (SI Appendix, Fig. S1),
which is within the range of the mechanical strengths reported for
the native lung tissue. In addition, the swelling ratios of the GelMA
hydrogels (double cross-linked) were significantly smaller (∼8 and
∼10% for 2D and 3D GelMA hydrogels, respectively) than those
photocross-linked with Irgacure 2959 alone (∼12 and ∼15% for 2D
and 3D GelMA hydrogels, respectively), as shown in SI Appendix,
Fig. S2A. Thus, we first photocross-linked our GelMA constructs
using Irgacure 2959 and then further chemically cross-linked them
using mTG to increase their stability as we have shown also in
the degradation profiles in SI Appendix, Fig. S2B. We have fur-
ther used collagen methacryloyl to fabricate an inverse opal
structure, demonstrating the feasibility of our approach to en-
gineer the alveolar lung model using different hydrogel bioma-
terials (SI Appendix, Fig. S3).
The structure (all based on GelMA below) was further charac-
terized by scanning electron microscopy, as illustrated in Fig. 2 A, ii,
Inset and SI Appendix, Fig. S4, in which an interconnecting window
between two adjacent sacs could be observed. The fluorescence
confocal images of the fluorescein isothiocyanate (FITC)-conju-
gated GelMA before and after alginate microbead removal further
verified their structure (Fig. 2 A, iii).
Fig. 1. The breathing human alveolar lung-on-a-chip. Schematics showing the distal lung, the breathing cycles, and the in vitro on-chip model of the
breathing alveolar lung.
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The alginate microbeads were prepared by electrospraying the
alginate solution into a CaCl2 solution for immediate physical
cross-linking (SI Appendix, Fig. S5). The influence of each pa-
rameter, including alginate concentration, voltage, needle di-
ameter, flow rate, and ring diameter, on the formation of the
microbeads was carefully studied (SI Appendix, Figs. S6–S10).
While a wide range of diameters could be conveniently achieved,
uniform alginate microbeads measuring ∼200 μm (201 ± 12 μm)
were selected for constructing the alveolar lung model since the
average size of each alveolus is ∼200 μm in diameter in the native
lung (33). Approximately 7,050 microbeads were packed into
three layers, resulting in a roughly 546.4-μm-thick inverse opal
structure. Such an inverse opal structure represented the minia-
ture alveolar lung model that featured the sac-like pores and the
interconnecting windows between the sacs, which resembles the
native human counterpart in both architecture and dimensions,
meaning that the two would also share the same unit surface area.
The dimension of the overall 3D GelMA scaffold was 8 × 10 ×
3 mm that comprised a layer of bulk GelMA base below the 546.4-
μm-thick inverse opal GelMA layer for improved stability.
Fig. 2. Fabrication of the alveoli-like 3D GelMA inverse opal structure and formation of the alveolar lung model. (A, i and ii) Schematics and bright-field
optical images showing the fabrication process of the alveoli-like 3D GelMA inverse opal structure. Alginate microbeads with uniform sizes (201 ± 12 μm)
were first assembled into a cubic close-packed lattice (Left); a 7% (wt/wt) GelMA solution was then infiltrated into the void spaces of the lattice and cross-
linked (Center). Finally, the alginate microbeads were selectively removed using EDTA, leaving behind an alveoli-like hydrogel structure (Right). (Scale bar:
100 μm.) A, ii, Right, Inset shows an scanning electron microscopy image of the interconnecting window between two adjacent sacs. (Scale bar: 20 μm; note
the shrinkage of the sac size comparing to optical images was caused by the sample-drying process for scanning electron microscopy imaging.) (A, iii)
Fluorescence confocal images illustrating the GelMA inverse opal hydrogel structure, where GelMA was chemically labeled with FITC. (Left) After infiltration
of the GelMA solution into the void spaces of the alginate microbead lattice and cross-linking, (Center) after removal of the alginate microbeads, and (Right)
3D reconstruction of the GelMA hydrogel structure. (Scale bars: 100 μm.) (B, i) Fluorescence confocal images showing the hAECs cultured in the GelMA inverse
opal hydrogel structures at 1, 7, and 14 d. Green, live cells; red, dead cells. (Scale bar: 100 μm.) (B, ii) Quantification of viability (Left) and proliferation (Right)
of the hAECs in the GelMA inverse opal hydrogel structures. *P < 0.05. (C) Confocal reconstruction view (Left) and sectional view (Right) of the hAECs after
culturing for 14 d in the GelMA inverse opal hydrogel structure, in which the fully confluent alveolar epithelium was formed. Green, F-actin; blue, nuclei.
(Scale bars: 100 μm.) (D) Confocal micrographs showing the presence of continuous tight junctions of the rim (Left) and bottom (Right) of a sac after culturing
for 14 d in the GelMA inverse opal hydrogel structure. White, ZO-1; blue, nuclei. (Scale bars: 50 μm.) (E) Representative image of an H&E-stained section of the
alveolar lung model after 14 d of culture. (Scale bar: 50 μm.)
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It should be noted that, although the human alveoli are not
necessarily homogeneous in size, in our model we pursued the use
of only uniform alginate microbeads as the sacrificial templates to
avoid unwanted interferences caused by the heterogeneity in the
alveolar sizes. Indeed, we have previously demonstrated that the
use of porous scaffolds with uniform pores is experimentally su-
perior to those with random pores even if the average pore size
falls in the same range (20, 21). In fact, we were also able to
fabricate the 3D inverse opal GelMA structures with different yet
uniform pore sizes using monodispersed alginate microbeads of
different diameters. The microbeads with sizes of 325.9 ± 10.5,
199.6 ± 1.1, and 156.3 ± 2.7 μm were used separately to fabricate
3D GelMA structures with corresponding pore sizes (SI Appendix,
Fig. S11). Likewise, we could also fabricate a 3D GelMA structure
with heterogeneous pore sizes by using randomly mixed
microbeads with three diameters (∼200, ∼250, and ∼300 μm) as
the template (SI Appendix, Fig. S12). The alginate microbeads
could be rapidly removed by treating with the 0.01 M EDTA so-
lution. The complete removal of the alginate microbeads from the
scaffold was confirmed by both scanning electron microscopy
imaging and X-ray energy dispersive spectroscopy (EDS) map-
ping, shown in SI Appendix, Fig. S13. In particular, EDS mapping
profiles suggested that while 1.3% of Ca2+ was detected in the
sample before removal of the microbeads, no Ca2+ (0%) was
measured at all after the removal. Thus, removal of both Ca2+ and
the alginate microbeads was complete.
To model the alveolar epithelium, we populated hAECs on the
surfaces of the sacs within the GelMA inverse opal structures.
Fluorescence confocal images revealed that the hAECs were al-
most rounded and crowded at day 1 postseeding, where they were
able to gradually spread and proliferate during the following days,
eventually covering the full surface areas of the alveoli-like sacs
(Fig. 2 B, i and C and SI Appendix, Figs. S14 and S15). The via-
bility of the hAECs on the surfaces of the pores in the porous
GelMA structures was observed to exceed 95% (Fig. 2B). The
proliferation of the cells was steady during the first 10 d of culture
and slightly slowed down afterward (Fig. 2 B, ii), possibly due to
the contact inhibition upon confluency of the cells on the surfaces
of the pores. The cell viability, proliferation, and spreading at the
different depths within a single layer of the sacs of the inverse opal
structure are shown in SI Appendix, Fig. S14. Indeed, fluorescence
confocal images suggested that these culture conditions resulted in
the formation of a confluent alveolar epithelium (Fig. 2, Movie S1,
and SI Appendix, Figs. S14 and S15). Significantly, the hAECs
were linked by a continuous presence of tight junctions as indi-
cated by Zonula occludens (ZO)-1 staining (Fig. 2D). Further-
more, hematoxylin and eosin (H&E) staining provided an
overview of the structure of the GelMA hydrogel and the cell
distributions, clearly validating the emulation of the alveoli-like,
interconnected sacs and the continuous monolayer of hAECs on
the pore surfaces (Fig. 2E).
Comparisons between 2D and 3D Cultures of the Human Alveolar
Epithelium. Reconstitution of the 3D structures and microenvi-
ronments of the tissues is vital for realizing their functions and
modeling pathophysiology in vitro (34, 35). To investigate the
advantages of our 3D GelMA inverse opal structures in the re-
capitulation of the pulmonary alveoli, the behaviors of hAECs
were carefully compared with those cultured on 2D GelMA
surfaces. The morphologies of the hAECs were further studied
by capturing scanning electron microscopy images (Fig. 3A) of
the cells cultured on both the 3D GelMA structures (Fig. 3 A,
Upper) and the 2D GelMA surfaces (Fig. 3 A, Lower) at days 3, 7,
and 14. Comparing with the slightly crowded and oftentimes
locally aggregated hAECs on the 2D GelMA surfaces during the
culture, the hAECs in the 3D GelMA structures appeared to be
flatter, where the formation of a smooth, confluent epithelium by
well-spread cells was apparent at day 14. The microscopic images
of hAECs cultured on the 2D GelMA surfaces are shown in SI
Appendix, Fig. S16. Moreover, the apparent proliferation rate of
the hAECs in the 3D GelMA structures was significantly higher
than that of the cells on the 2D surfaces (SI Appendix, Fig. S17).
Nevertheless, when normalized (Fig. 3B), there were no significant
differences between the two configurations anymore during the
culture period of 10 d. The hAECs in the 3D GelMA structures
became higher in numbers than those on the 2D surfaces at day
14, most likely due to the presence of the larger total surface area
within the 3D GelMA structure as compared with the 2D surface,
at ∼2 cm2 in the former vs. 0.8 cm2 for the latter despite that they
share the same planar size of 8 × 10 mm. Most importantly, the
3D GelMA scaffolds provided an optimal geometry and micro-
architecture for cell spreading and proliferation compared with
the planar surfaces, which possibly promoted the cellular process
such as adhesion, proliferation, and migration. These observations
indicated that the 3D culture provided an optimal geometry for
cell spreading and proliferation compared with the planar culture
when both substrate materials were the same GelMA with similar
local mechanical properties, both close to that of the normal hu-
man lung tissue (29).
Apoptosis is a fundamental cellular process that is necessary for
the maintenance of tissue homeostasis in adult organisms (36). The
apoptotic activities of the cells were analyzed via caspase-3/7 staining
of hAECs and flow cytometry analyses of annexin V-FITC– and
propidium iodide (PI)-stained hAECs both on 2D GelMA surfaces
and in 3D GelMA structures. Interestingly, it was found that the
mean fluorescence intensity of caspase-3/7 was higher for the cells
grown on the 2D GelMA surfaces compared with those in the 3D
GelMA structures (Fig. 3C and SI Appendix, Fig. S18). Similarly,
the flow cytometry analyses of annexin V-FITC– and PI-stained
hAECs at day 14 and day 22 showed that the overall proportion of
late apoptotic/necrotic hAECs on the 2D GelMA surfaces was
increased over the culture period compared with those in the 3D
GelMA structures (Fig. 3D and SI Appendix, Fig. S19). While the
proportions of early apoptotic cells were higher in 3D structures,
the proportions of the late apoptotic/necrotic cells were higher on
the 2D GelMA surfaces, at both day 14 (Fig. 3D) and day 22 (SI
Appendix, Fig. S19). It is therefore hypothesized that our unique
3D GelMA inverse opal structure resembling that of the human
alveoli could possibly provide the cells with an in vivo-like mi-
croenvironment, which promoted optimal cell–ECM and cell–cell
interactions.
To explore the differentially expressed genes to detect biological
changes in hAECs cultured in 2D and 3D, we performed addi-
tional transcriptome profiling through gene microarray analyses.
Other than the 2D GelMA surfaces, we further included another
control group based on the 2D PDMS surfaces (a commonly used
substrate in various organ-on-chip models, including those of the
lung) to compare with the 3D GelMA structure-based hAEC cul-
ture. Scatterplots and the Venn diagram (SI Appendix, Fig. S20 A
and B) were generated for the three comparisons (i.e., 3D GelMA
vs. 2D PDMS, 3D GelMA vs. 2D GelMA, and 2D GelMA vs. 2D
PDMS). We calculated the normalized expression values (frag-
ments per kilobase per million mapped reads) of every gene ana-
lyzed in the three groups, and those values with greater than twofold
increase or decrease with a false discovery rate of less than 0.05 (q
value < 0.05) were considered as the differentially expressed genes.
Interestingly, the 3D GelMA vs. 2D PDMS comparison demon-
strated that there were 4,757 differentially expressed genes (2,646 up-
regulated and 2,111 down-regulated); for 3D GelMA vs. 2D GelMA,
there were 2,396 differentially expressed genes (1,352 up-regulated
and 1,044 down-regulated), while for 2D GelMA vs. 2D PDMS,
there were 5,175 differentially expressed genes (2,553 up-
regulated and 2,622 down-regulated) (SI Appendix, Fig. S20B).
To elucidate the biological processes on the different culture
substrates, functional gene ontology (GO) and Kyoto Encyclope-
dia of Genes and Genomes (KEGG) pathway enrichment analyses
4 of 10 | PNAS Huang et al.



































were further performed (SI Appendix, Fig. S20C). Through
K-means clustering analysis of the differentially expressed genes in
the three groups, heat maps relating to GO and KEGG enrich-
ment analyses of clusters showed similar gene expression trends
(Fig. 3E and SI Appendix, Fig. S20 D and E).
We have specifically focused on some key functional cate-
gories to better understand the major differences for the hAECs
cultured on 2D PDMS, 2D GelMA, or 3D GelMA, exhibited as
the GO enrichment analysis in Fig. 3 E, i and KEGG enrichment
analysis in Fig. 3 E, ii. The genes associated with ECM–receptor
interactions, focal adhesion, tumor necrosis factor (TNF) sig-
naling pathway, and small-cell lung cancer in the clusters had a
monotonically decreasing trend from 2D PDMS and 2D GelMA
to 3D GelMA cultures, while oxidative phosphorylation in the
cluster showed an increasing trend (SI Appendix, Fig. S20).
Similarly, biological processes regarding mitochondrial biogen-
esis also possessed an increasing trend in the order of 2D PDMS,
2D GelMA, and 3D GelMA cultures. Mitochondria provide the
cells with adenosine triphosphate through the oxidative phos-
phorylation activity, and up-regulation of these pathways could
provide more energy to help maintain the functionality of the
cells (37, 38). Specifically, heat maps were produced to compare
differentially expressed genes involved in ECM–receptor inter-
actions and the TNF signaling pathway. Integrin-β4 (ITGB4),
which is one of the transmembrane receptors for ECM proteins,
can form a stable attachment to the basal membrane in polarized
epithelial cells through the formation of hemidesmosomes (39)
and also has a significant impact on signaling events that stimulate
migration and invasion (40). It was observed that the hAECs
expressed more ITGB4 and interleukin-6 (IL-6) in 2D conditions
(both GelMA and PDMS) than in 3D GelMA (Fig. 3F), possibly
indicating a response to the more unnatural 2D microenviron-
ments. Focal adhesions are key transducers of outside-in signaling
that enable cells to sense cues from the ECM and generate forces
(41). In 2D cultures, especially for PDMS, up-regulation of focal
adhesion genes and ECM–receptor interaction genes might be
caused by the stiff and pathologically activated surfaces (41, 42).
Prior studies further reported that TNF-induced death signaling
induced alveolar epithelial dysfunction in acute lung injury (43)
and also, the increase of IL-6 expression in lungs with diffuse al-
veolar damage (44, 45). Collectively, these analyses hinted that our
3D GelMA inverse opal structure provided better capabilities to
maintain and promote the functions of hAECs in a more in vivo-
like manner compared with 2D models, particularly those based
on the planar PDMS surfaces.
Construction of a Breathing Human Alveolar Lung-on-a-Chip Model.A
schematic diagram of the alveolar lung-on-a-chip (Upper) and a
photograph of an actual device are shown in Fig. 4A. The fabri-
cation process of the chip is schemed in SI Appendix, Fig. S21. The
chip was composed of the 3D porous GelMA inverse opal scaffold
(red part in the schematic) bonded to a PDMS chip. The PDMS
support was designed to provide the 3D hydrogel with the medium
supply and cyclic mechanical actuations. The medium supply was
Fig. 3. Comparisons of the alveolar epithelium formation for hAECs cultured on 3D and 2D substrates of GelMA and PDMS. (A) Scanning electron microscopy
images of the hAECs cultured on/in the 3D GelMA inverse opal structure (Upper) and the 2D GelMA hydrogel (Lower) at days 3, 7, and 14. (Scale bars: 25 μm.)
(B) Normalized proliferation of hAECs on the two GelMA surfaces. ***P < 0.001. (C) Caspase-3/7 fluorescence signal analysis and annexin V-FITC/PI flow
cytometry plots of hAECs on the two GelMA surfaces. **P < 0.01. (D) Flow cytometry analyses of annexin V-FITC– and PI-stained hAECs cells at day 14. (E)
K-means clusters of the genes for (i) GO enrichment and (ii) KEGG enrichment analyses of hAECs cultured on 2D PDMS, on 2D GelMA, and in 3D GelMA for 14
d. (F) Heat maps showing differential genes expressions relating to (i) ECM–receptor interactions and (ii) TNF signaling pathway of hAECs cultured on 2D
PDMS, on 2D GelMA, and in 3D GelMA for 14 d. a.u.: any unit; PI3K-Akt: phosphatidylinositol 3-kinase-protein kinase B; HIF-1α: hypoxia-inducible factor-α.
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realized by slowly infusing the medium through the open channels
at the bottom of the PDMS chip. The cyclic mechanical movements
were applied to the 3D hydrogel via applying the programmed
negative pressures to the two side chambers at the frequency of
0.2 Hz (the normal breath frequency of human).
The mechanical movements of the chip allowed the airflow in
and out of the embedded 3D GelMA structure. There are some
reports that have focused on building and simulating the airflow
in the artificial alveoli (46, 47); however, only few successfully
reconstituted the 3D structures of the human alveolar sacs. Herein,
we demonstrated the airflow in and out of the alveoli-like structure
in our inverse opal alveolar lung model during a breathing cycle, as
shown in the simulation results in SI Appendix, Fig. S22 A, C, and E
as well as in Movie S2. During the “breathing” of the chip, the air
gradually flowed into and then out of the inverse opal sacs spon-
taneously due to the volume change-induced pressure variation with
velocity values and Reynolds numbers (0.71 to 1.70), which are very
similar to those found in the real human alveoli. In addition, direction
of the airflow changed according to the structural framework within
the inverse opal alveolar lung model, especially in correspon-
dence at the “alveolus–alveolus” interfaces. On the contrary, in
the control 2D model, the airflow followed nonphysiological
straighter paths without showing rapid changes of directions (SI
Appendix, Fig. S22 B, D, and F).
After seeding the hAECs in the 3D GelMA inverse opal
structures in the chips, the cells were cultured for 14 d. Live/dead
images revealed that the cell viability remained high after 14 d of
static culture in the chips (Fig. 4 B, control). When the cyclic
stretch was applied, the hAECs grown on the surfaces of the pores
could “breathe” along with the cyclic mechanical movements that
stretched the GelMA structure, where the average size of alveoli
was observed to expand by ∼8% from the state of “breath out” to
“breath in” (Fig. 4C and Movie S3). This value is within the 5 to
15% physiological range of strain experienced by the alveoli in the
human lung (10). It was, in fact, convenient for us to control the
strains or breathing frequencies on the chip as needed by varying
the size of the two side chambers or the frequency of the negative
pressure applied. As shown in Movie S4, our chip-based model
functioned well under a range of strain levels of 5, 10, and 15%, as
well as breathing frequencies of 0.1, 0.2, 0.4, and 0.8 Hz.
An ALI was also created for the hAECs in the chip by removal
of the medium from the sacs and supplying the medium through
the parallel channels underneath the GelMA structure at the
bottom of the chip. The relatively low thickness (<3 mm) of the
GelMA hydrogel and its nano-/microscale porosities were be-
lieved to enable efficient medium transport to support cellular
functions. To confirm the sufficient supply of nutrients within the
top layer of the 3D GelMA inverse opal structure, we assessed
the diffusion of both small molecules (FITC) as well as larger
molecules (FITC-dextran, Mw = 10 kDa). It was found that the
diffusion of both types of molecules across the entire GelMA
structure occurred within relatively short periods (SI Appendix,
Fig. 4. Construction of the alveolar lung-on-a-chip model. (A) Schematic representing the alveolar lung-on-a-chip (Upper) and photograph of a device
without the GelMA inverse opal structure to show the underlying fluidic channels (Lower). (Scale bar: 5 mm.) (B) Fluorescence images showing the viability of
the hAECs cultured in the chips without and with the breathing events. Green, live cells; red, dead cells. (Scale bar: 100 μm.) (C) Micrographs showing the
expansion of the sacs under a strain of 8%. (Scale bar: 100 μm.) (D) Images of H&E-stained sections showing the epithelium formation in the chips without and
with the breathing events. (Scale bar: 50 μm.) (E) ZO-1 staining showing the tight junction formation of the epithelium in the chips without and with the
breathing events. White, ZO-1; blue, nuclei. (Scale bar: 50 μm.) (F) The quantified levels of secreted cytokines IL-8, IL-6, IL-1β, MCP-1, and GM-CSF by hAECs
cultured in the chips without and with the breathing events. All analyses were performed at 14 d of culture.
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Fig. S23). Since the diffusion is a continuous process, this obser-
vation potentially suggested good transport of various components
within the culture medium through the GelMA structure.
Indeed, the hAECs cultured within the alveolar lung-on-a-chip
devices remained viable after the incorporation of the ALI and the
application of the breathing events for 48 h (Fig. 4 B, breathing),
while the formed alveoli-like epithelial monolayer within the GelMA
inverse opal structure could be completely preserved as revealed
in the H&E-stained sections (Fig. 4D). Moreover, the presence of
cyclic mechanical strains seemed to have promoted the formation
Fig. 5. The effects of smoking and SARS-CoV-2 pseudoviral infection on the alveolar lung-on-chip model. (A) Schematic diagrams showing the smoking
alveolar lung-on-a-chip. (B) Live/dead staining of the hAECs in the alveolar lung-on-a-chip devices before and after smoking. Green, live cells; red, dead cells.
(Scale bar: 100 μm.) (C) Quantification of cell viability for hAECs. Control: without breathing and smoking; breathing: with breathing but without smoking;
and breathing + smoking: with breathing and smoking. (D) Confocal fluorescence images showing the effects of smoking on tight junctions of the alveolar
epithelium, revealed by ZO-1 staining. White, ZO-1; blue, nuclei. (Scale bar: 100 μm.) (E) Confocal fluorescence images showing induction of oxidative stress
with smoking. Green: 4-HNE; blue, nuclei. (Scale bar: 100 μm.) (F) The quantified levels of secreted cytokines IL-8, IL-6, IL-1β, MCP-1, and GM-CSF by hAECs
cultured in the chips. All analyses were performed at 14 d of culture, and smoking was conducted for 75 min. (G) Fluorescence confocal images showing the
expression of ACE2 receptors by hAECs in the GelMA inverse opal structures at day 14. Red, ACE2 receptors; blue, nuclei. (Scale bar: 50 μm.) (H) Fluorescence
microscopic images showing the live/dead staining for hAECs in the GelMA inverse opal structures after (i) pCoV-VP infection without antiviral drugs, (ii)
pCoV-VP infection in the presence of amodiaquine (5 μM), (iii) pCoV-VP infection in the presence of remdesivir (10 μM), and (iv) pCoV-VP infection in the
presence of hydroxychloroquine (40 μM). Green, live cells; red, dead cells. (Scale bar: 100 μm.) (I) MTS assay showing metabolic activities of hAECs in the GelMA
inverse opal structures after pCoV-VP infection in the absence and presence of antiviral drugs. *P < 0.05; **P < 0.01; ***P < 0.001.
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of tight junctions, indicated by ZO-1 staining (Fig. 4E) (48). The
levels of secreted cytokines including IL-8, IL-6, IL-1β, monocyte
chemoattractant protein-1 (MCP-1), and granulocyte-macrophage
colony-stimulating factor (GM-CSF) were further profiled; they
were all slightly reduced upon breathing stimulation, yet no sig-
nificant differences could be found (Fig. 4F).
Analysis of Cigarette Smoking Effects on the Alveolar Lung-on-a-Chip
Model. Cigarette smoking is one of the major factors leading to
the development of COPD, currently the third leading cause of
chronic morbidity and mortality worldwide (2, 49, 50), as well as
resulting in lung cancer as the most common lethal neoplasm
(51). Since the alveolar epithelium is the barrier between the
inhaled air and the underlying components (52), the establish-
ment of a smoking alveolar lung-on-a-chip model to examine the
distal lung injury and study the effects of smoking on the alveolar
epithelium becomes important. While a smoking lung-on-a-chip
platform was previously demonstrated using airway epithelial
cells on a synthetic polyethylene terephthalate membrane (53),
no model currently exists for the distal lung (i.e., the alveoli). Our
smoking alveolar lung-on-a-chip model consisted of a smoking
device (53, 54) and an additional compartment on top of the
breathing alveolar lung-on-a-chip platform to mimic the airway–
alveoli transport route (Fig. 5A). After smoking ∼10 cigarettes and
further culturing for 24 h, dead cells within our alveoli model
showed an increase (Fig. 5B), and the viability of hAECs was sig-
nificantly decreased compared with normal breathing and control
groups (Fig. 5C). The apoptotic activities of the cells before and
after the application of the cigarette smoke were analyzed via
caspase-3/7 staining of hAECs on/in both 2D and 3D scaffolds (SI
Appendix, Fig. S24). Consistent with the cultures without the chips
(Fig. 3C and SI Appendix, Fig. S18), hAECs on 2D GelMA in the
chip also showed a higher apoptotic tendency (SI Appendix, Fig.
S24A) as compared with those in 3D GelMA structures (SI Ap-
pendix, Fig. S23B). The smoking further resulted in the increase of
apoptosis of hAECs in both configurations (SI Appendix, Fig.
S24 A–C). This observation was, in addition, reflected in cellular
activity assay (SI Appendix, Fig. S24D).
In addition, the tight junctions between the hAECs were
partially damaged after smoking (Fig. 5D). The oxidants in ciga-
rette smoke can induce cellular injuries (55), where 4-hydroxy-2-
nonenal (4-hydroxynonenal [4-HNE]) is a major product of lipid
peroxidation and a marker of oxidative stress (56, 57). 4-HNE
can react with DNAs and proteins to produce various adducts
that can lead to cell apoptosis, and the 4-HNE expression level
in the alveolar epithelium is negatively correlated with pulmo-
nary functions and contributes to the pathogenesis of various
pathological manifestations such as COPD (58). Our results in-
dicated an elevation in the intensity of nuclear 4-HNE staining
postsmoking (Fig. 5E), and such a high expression of 4-HNE
may further induce downstream cellular damage. As a result,
the soluble cytokine levels of IL-8, IL-6, IL-1β, MCP-1, and
GM-CSF after smoking slightly declined compared with the
normal breathing group, suggesting that the functions of hAECs
to inhibit proinflammatory responses were compromised
when they were exposed to cigarette smoke, consistent with
literature (53).
Analysis of SARS-CoV-2 Pseudoviral Infection and Treatment Efficacies
on the Alveolar Lung-on-a-Chip Model. COVID-19 caused by
SARS-CoV-2 has led to a global public health crisis and is asso-
ciated with high mortality, mostly caused by acute respiratory
distress syndrome (59, 60). As the lungs are the first body organ
affected by COVID-19, we further assessed the applicability of our
alveolar lung-on-a-chip to investigate SARS-CoV-2 pseudoviral
infection. In addition, the antiviral efficacies of two clinically ap-
proved antiviral drugs, remdesivir (61) and hydroxychloroquine
(62), as well as an antimalarial drug, amodiaquine (63), were
evaluated. The latter has also been given to individuals infected
with SARS-CoV-2 (64). Since it has been well recognized that
SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) as a
receptor for cellular entry, prior to SARS-CoV-2 pseudoviral
particle (pCoV-VP) infection on the alveolar lung-on-a-chip, we
first detected the expression of ACE2 receptors by hAECs grown
on the surfaces of the alveolar sacs. The hAECs showed a higher
level of expression of ACE2 receptors as shown in Fig. 5G and SI
Appendix, Fig. S25A. The chips were then inoculated with pCoV-
VPs at multiplicity of infection (MOI) of 0.5 for 48 h to identify
the virus susceptibility in vitro in the presence and absence of
antiviral drugs. At 48 h postinfection, the infection of hAECs with
mcherry-labeled pCoV-VPs was observed under a fluorescence
microscope (SI Appendix, Fig. S25B), and cytopathic effect of pCoV-
VPs was assessed by live/dead assay (Fig. 5H and SI Appendix, Fig.
S25C) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Fig. 5I). The results
showed that the cytopathic effects of pCoV-VPs were decreased
by approximately 21.4, 30.0, and 11.3% at 5 μM amodiaquine,
10 μM remdesivir, and 40 μM hydroxychloroquine, respectively
(Fig. 5I). Thus, these drugs significantly inhibited the infection-
induced hAEC death by the SARS-CoV-2 pseudotyped viral
particles expressing the SARS-CoV-2 spike proteins in our alveolar
lung-on-a-chip.
Conclusions and Perspectives
This study provided an example of recreating the architecturally
relevant alveolar lung-on-a-chip model and demonstrated its
structural and functional features. We have successfully recon-
structed some of the key aspects of the human pulmonary alveoli,
including the microarchitecture, the ECM microenvironment, the
ALI, and the mechanical breathing events. The alveolus in the lung
is one of the most important structural determinants of the ar-
chitecture of the respiratory parenchyma and lung functions. Our
breathing alveolar lung-on-a-chip model could broadly reproduce
the 3D anatomical structures and functions of the alveoli through
the use of a precisely defined 3D porous GelMA hydrogel based on
an inverse opal structure, while the breathing function was realized
by situating the hAEC-populated GelMA structure in PDMS chip
device. Based upon the breathing alveolar lung-on-chip model,
we subsequently built a cigarette-smoking alveolar lung-on-a-chip
platform, where the negative effects of smoking on the hAECs
could be readily explored. We further demonstrated the applica-
bility of our alveolar lung model for investigating SARS-CoV-2
pseudoviral infection and treatment efficacies of antiviral drugs
such as hydroxychloroquine, remdesivir, and amodiaquine. While
remdesivir and amodiaquine have been approved by the Food
and Drug Administration to treat COVID-19 (64), in vitro and
in vivo studies have shown the discrepancies in antiviral activity
of hydroxychloroquine against SARS-CoV-2 (62).
We have also showcased the possibility of creating the alveolar–
capillary interface, which is another key microstructure in the
human distal lung that enables the gas exchange in the alveoli by
incorporating the human umbilical vein endothelial cells into the
matrix of the GelMA inverse opal hydrogel to form the micro-
vascular network surrounding the sacs (SI Appendix, Fig. S26). In
addition, to investigate the capability of our strategy to reconsti-
tute pathological models of the lung or in particular, lung cancer,
we also built a nonsmall-cell lung cancer model with A549 cells.
As shown in SI Appendix, Fig. S27, the A549 cells could form a
good alveolar structure in our platform with good cell viability and
morphologies (note the multilayered growth of the A549 cells in
some regions in comparison with the monolayer epithelium formed
by normal hAECs).
Although surfactant lining layer at the ALI is extremely im-
portant for maintaining the alveolar functions, hAECs that we
used in this study were commercially sourced, where the vendor
unfortunately did not provide any information on AEC types I/II.
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It would be indeed very interesting for us in our future work to
introduce defined populations of hAECs in our model, to study their
effects on alveolar functions and pathologies such as infections.
While our system has some limitations, this example of the
miniature alveolar lung-on-a-chip platform provides the founda-
tion and can be readily expanded in the future to provide full
functionality of the alveolar units in vitro to provide a niche for
lung and lung disease modeling and research.
Methods
SI Appendix, Supplementary Text has detailed experimental procedures that
describe the 1) synthesis of alginate microbeads; 2) synthesis of GelMA; 3)
fabrication of GelMA inverse opal structures; 4) fabrication of the GelMA
inverse opal structure-embedded chip device; 5) fabrication of the smoking
device; 6) cell culture in 3D GelMA inverse opal structures; 7) cell culture on
2D GelMA surfaces; 8) construction of the alveolar lung-on-a-chip; 9) cellular
characterizations; 10) scanning electron microscopy imaging; 11) apoptosis
analyses; 12) microarray analyses; 13) analysis of chemokines and cyto-
kines; 14) computational simulations; 15) SARS-CoV-2 pseudotyped virus
production and infection of the alveolar lung-on-a-chip; and 16) statistical
analyses.
Data Availability. All study data are included in the article and/or supporting
information.
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